• Čeština
  • English
  • Русский



    Project ARICE - Armenian Research Infrastructure on Cancer Research, is a twinning project from the biggest European  research program HORIZON 2020, that aims to increase the research infrastructure capacities in the field of cancer research in Armenia, through integrating a robust pathology background with state-of-the-art biobanking to a research-ready data structure. This will be achieved by establishing close cooperation with the leading expert-institutions in the field (Medical University Graz, Charles University and IARC) as well as by facilitating spread of the competences at institutional, national and regional level. Cancer research infrastructure has been chosen as the focus because Armenia has a very high incidence and mortality of cancers, as well as a very high prevalence (according to incidence) among rare malignant diseases, while it underperforms in cancer research when compared to the EU average. ARICE will ensure cancer research infrastructure gets appropriate attention in order to support further local research in Armenia and in the wider Caucasus region, including former Soviet Republics. New scientific developments in the field of cancer prevention, in particular in biomarker research and large population-based investigations are in place to facilitate success in research in this field. The ARICE project is going to be an important step for reaching the set goals both efficiently and effectively. The competences acquired in this field during the project realization will be easily transferable to other fields of research related to medicine, biology and medical ethics, health-economics and biostatistics. Involvement of researchers from multiple specialities (physicians of different specialities, biologists, data management specialists) hosted by the Yerevan State Medical University (YSMU) will ensure this smooth transfer of expertise.

  • 2ND Biospecimen Research Symposium

    Berlin, 5.-6. February 2019, Mercure Hotel MOA Berlin

    Focus on Quality and Standards

    After the success of the first symposium, the second symposium focused on three main sessions; (i) in-vivo pre-analytics factors, (ii) ex-vivo pre-analytics factors and (iii) microbiome, covering the most innovative topics in the field currently. The topics of this meeting were presented by experts in their respective domains. The topics included cancer research, which was also the subject of the key note lecture, employing DNA to RNA sequencing and exosome research. Special attention was paid to applications of metabolome and proteome research as well as to specific requirements needed to produce reliable data for the interpretation of our circadian rhythms.

    The symposium was co-organized by the German Biobank Node (GBN), a member of the pan-European biobank infrastructure BBMRI-ERIC. Together with a number of biobanks that have joined forces within the German Biobank Alliance (GBA) there is currently establishing a national biobank infrastructure. The biobanks of this alliance are operating in an IT network to enable cross-biobank queries while complying with common quality standards to allow cross-biobank compilation of biomaterial collections.

    Biobank Pilsen was presented by two posters:

    1) Kinkorova J., Topolcan O., Karlikova M., Kucera R.: Fibroblast Growth Factor (FGF) 23 – Is There Any Potential To Be a Tumor Marker for a Clinical Practice?

    2) Svobodova S., Karlikova M., Topolcan O., Pecen L., Pestova M., Kott O., Treska V., Slouka D., Kucera R.: PIVKA-II – a new promising biomarker of hepatocellular carcinoma.

  • Personalised Medicine in Action

    Personalised Medicine in Action

    The first conference ‘Personalised Medicine in Action’ of the International Consortium for Personalised Medicine (ICPerMed) was held in Berlin, Germany on 20-21 November, and assembled more than 300 experts from 32 countries. At the conference best practice examples for successful implementations of personalised medicine approaches in Europe and beyond were presented.

    "The funding of basic research in the broad field of personalised medicine is starting to pay off. Our conference programme showed that today patients already benefit from ground-breaking personalised therapies, e.g. for lung cancer or metabolic diseases...Fast developing technologies, successful biomedical research and wise policy making has led to several excellent pilots in national and regional health care systems across Europe.

    Policy makers, research funding agencies, researchers and health care systems need to learn from this good practice to create benefits for all citizens and patients in Europe and beyond", said O’Driscoll, Director of Research Strategy and Funding at the Health Research Board (Ireland).

    The first ICPerMed conference was opened by high-level representatives of the German Federal Ministries for Research & Education and Health. This, together with the welcoming speeches of representatives of the European Commission (DG RTD & CNECT) and two Members of the European Parliament, underlined the outstanding position of personalised medicine and ICPerMed in the European research agenda and at political level.

    The conference programme was dedicated to successful examples for translation of personalised medicine research into added value for the patient, such as the routine implementation of personalised care for lung cancer or rare diseases. High-level key note talks on different aspects of personalised medicine broadened the conference perspective and provided international views on personalised medicine in China, India and the US.

    Panel discussion of the Swedish Best Practice Example of the implementation of personalised medicine approaches

  • Biobanking, London, October 25-26, 2018

    Biobanking, London, October 25-26, 2018

    The Oxford Global team organize annually the co-events, summits, or congresses, aiming to connect related research topics. This year four events: 7th Annual Cell Culture & Bioprocessing Congress, 5th Annual Stem Cells Congress, 4th Annual Cell& Gene Therapy Congress and Biobanking Congress, took place in Novotel London West hotel and Congress Centre in London in October 25-26.

    Over 150 leading biobanking, biomarker and sample management experts came together to discuss the most recent developments within research and industry. The Biobanking congress brought together key speakers from Europe’s biobanks to explore key insights into biosample management, standards, quality management as well as future advances in areas such as regulations and collaboration. The presentations by leading pharmaceutical companies featured biobanking and case studies in biomarker-driven clinical trials and the role of biobanking in the future of personalised medicine was discussed.

    University Hospital in Pilsen was presented by the talk on „Personalised Medicine in Oncology“by Judita Kinkorová, and a panel discussion: „How Biobanks Facilitate Personalised Medicine“.

    The congress offered the participants the platform for future collaborations. In the picture is Balwir Matharoo-Ball, deputy director of Nottinghem Health Science Biobank and a head of working group ESBBTranslate, for industry- academia collaboration (European, Middle Eastern & African Society for Biopreservation and Biobanking, ESBB).

  • 45th ISOBM Congress

    Hamburg, Germany, November 24 – 27, 2018
    Congress web page: http://isobm-conference.org/
    Our Theme - Tumor Diagnosis and Therapy - Role of Biomarkers
    The 2018 Congress has the aim to bring together participants active in all fields of basic and clinical research in Oncology, in order to optimize clinical results in cancer prevention, diagnosis and therapy.
    More than before, Biomarkers hold out promise for improving the outcome of cancer patients by optimization of diagnostic procedures in combination with clinical parameters and various imaging methods. By continuous development of standardization, quality contol and automatization, as well as by applying new individualized targeted treatments, we succeed now to improve patients state and survival.The new therapeutic agents can be combined with the established chemo-radiotherapy of Cancer disease.
    Relevant new findings in research, diagnosis and clinical Oncology - as well as technical developments, standardization and quality control, will be presented by opinion leaders in Oral and Poster presentations, along with panel discussions and special topic seminars. A wide range of companies and commercial exhibitors will show their products and services, enabling a valuable exchange between different suppliers and users, colleagues, as well as members of the technical staff. In addition, as during recent years, the EGTM (European Group of Tumor Markers) will present their Guidelines on optimal use of Tumor Markers and their clinical interpretation.
    Hamburg is a beautiful metropolis in the northern part of Europe and Germany, well-known for sightseeing in the centre with the Alster and the Elbe and for social events, shopping, dining, museums of art and science/ history. In addition, the congress time in November will also allow the participants to enjoy the first days of the well-known Christmas Markets in the city of Hamburg.
    Please allow us to look forward to host you at the ISOBM Congress in Hamburg, November 2018, to exchange ideas and expertise in an International forum and to enjoy the hospitality of Hamburg.
    Prof. Vivian Barak - Congress President

  • ISBER 2018

    Dallas, USA, May 20 – 24, 2918

    Annual meeting and Exhibits
    The title of the congress was: Thinking BIG in TEXAS, with the subtitul: Seazing big opportunities in biobanking through data, collaboration and innovation.

    The 2018 Annual Meeting programe was very rich included seven symposia sessions, four oral Contributed Paper Sessions, an Innovative Technologies Sessions, and opportunuties to attend special workshops and additional Corporate Partner Symposia. Additional networking opportunities included: the welcome reception, discussions with vendors and interactions with poster presenters (alltogether 164 posters, from there three were from Biobank in Pilsen and Department of Immunochemistry, University Hospital Pilsen). The number of participants was really great more then 700, mainly from the USA, Canada, China and Africa. The organizers recieved 212 abstract for oral presentations, from where 28 were selected.

    University Hospital in Pilsen, biobank Pilsen was introduced by one oral presentation: Kinkorová J., Dolejšová O., Fuchsová R., Topolčan O., Kučera R. a Karlíková M.: Systematic Sample Collecting Can Help with the Individualisation of Therapy (An Example of Improvement of Prostate Cancer Management), in the Contributed Paper Session 4: Advancing the Norms: Human Repositories; and three posters.
    More information can be found on web pages of the conference: http://meetings.isber.org/2018/
    Next Annual Meeting will be in Shanghai, May 7 – 10, 2019.